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A 32-year-old Chinese female never smoker presented withpersistent cough in June 2009, and imaging studies re-
vealed a right hilar mass. An endobronchial biopsy of the
tumor revealed a moderately differentiated mucinous adeno-
carcinoma that was cytokeratin 7 (CK7) positive, CK20
negative, transcription tissue factor-1 (TTF-1) positive, and
mucicarmine positive. Initial molecular analysis revealed the
tumor to be both epidermal growth factor receptor and KRAS
wild type. Her staging workup revealed metastasis to the liver
and brain. She underwent stereotactic radiosurgery of her
brain metastases that was followed by six cycles of cisplatin/
pemetrexed/bevacizumab combination chemotherapy fol-
lowed by bevacizumab maintenance therapy, with a partial
response to treatment. In November 2009, she decided to
undertake a treatment holiday for 3 months. By February
2010, however, her disease had progressed, and she com-
menced single-agent erlotinib treatment but had documented
disease progression after 6 weeks. She was referred by her
treating oncologist for possible enrollment into the phase I
crizotinib trial because her clinical profile—young age, ade-
nocarcinoma histology, never-smoking status, and most im-
portantly her tumor is wild type for epidermal growth factor
receptor and KRAS—fits the profile of an anaplastic lym-
phoma kinase (ALK)-positive patient with non-small cell lung
cancer (NSCLC).1 The patient signed an informed consent for
molecular screening of her tumor for ALK translocation and
MET amplification for enrollment onto the phase I trial of
crizotinib (PF02341066), a dual inhibitor of both ALK and
MET oncogenes (A8081001, NCT00585195). While awaiting
for the screening results, she enrolled in another clinical trial
of docetaxel in combination with a novel vascular disrupting
agent but her disease continued to progress rapidly after one
cycle of treatment. The results from the crizotinib prescreen-
ing showed her tumor to be positive for an ALK gene
rearrangement using a break-apart fluorescent in situ hybrid-
ization (FISH) probe (15% of cells harboring isolated 3
ALK FISH signals)1,2 (Figure 1). She was thus enrolled onto
the molecularly enriched cohort of the crizotinib phase I
study. Further molecular testing confirmed that the tumor
harbored the EML4-ALK variant 1 transcript (E13; A20),
which is the most common EML4-ALK variant.3
At the time of study entry, although her Eastern Coop-
erative Oncology Group performance status was 0, she had
developed a persistent cough, daily low-grade fevers, an-
orexia, and right neck pain due to tumor invasion of the right
subscapalaris muscle as shown in her pretreatment baseline
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diagnostic computed tomography (CT)/18F-fluorodeoxyglu-
cose positron emission tomography (18-FDG PET) fusion
scan (Figure 2A). The patient started on crizotinib 250 mg
twice a day orally in June 2010 and 3 days later reported that
the daily low-grade fevers had disappeared, her right neck
pain had resolved, and her cough had significantly decreased.
By her week 2 visit, she had gained 1.5 kg of weight, and her
cough had also completely resolved. The 18-FDG PET/CT
FIGURE 1. Break-apart ALK FISH assay. FISH, flu-
orescent in situ hybridization.
FIGURE 2. A, Coronal diagnostic CT/PET fusion images 7 days before starting crizotinib. B, Coronal diagnostic CT/18-FDG
PET fusion images 14 days after starting crizotinib. CT, computed tomography; 18-FDG PET, 18F-fluorodeoxyglucose positron
emission tomography.
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fusion performed on day 14 of the study showed a 70.5%
decrease in maximum standard uptake value activity (Figure
2B) with a corresponding 36.4% decrease in the total tumor
measurement by RECIST (version 1.1). She continued to do
well, and the week 4 diagnostic 18-FDG PET/CT fusion scan
revealed a continued response with a 72.3% decrease in the
maximum SUV from baseline and a corresponding 45.1%
decrease in tumor measurement by RECIST from baseline.
She returned to work full time as a software engineer, and her
week 8 CT scan confirmed continued clinical response with a
further 47.5% decrease in her total tumor measurement from
her baseline values.
DISCUSSION
ALK gene rearrangement represents a recently discov-
ered molecular alteration in a subset of NSCLC.4 Crizotinib
(PF-02341066), a dual ALK and MET inhibitor, has now
demonstrated significant clinical activity in ALK-positive
patients with NSCLC in an ongoing clinical trial (A8081001,
NCT00585195).2 Within this trial, there have been numerous
anecdotal examples of significant symptomatic relief reported
by our patients within days after starting crizotinib. Within
the ALK-positive molecularly enriched NSCLC cohort who
achieved objective response to crizotinib, objective responses
were seen in 44.7% of these patients within less than 8 weeks
with 74% of these patients responding by 12 weeks.5 In this
report, we present clinical and radiographic evidence con-
firming the extreme rapidity of clinical benefit and symptom-
atic relief in an ALK-positive patient with NSCLC treated
with crizotinib. This report also demonstrates that functional
imaging with 18-FDG PET is a valid method to detect
response to crizotinib.
The radiologic evidence of disease response in this case
is reminiscent of the rapidity of responses in gastrointestinal
stromal tumor to imatinib.6 It also attests to the principle of
oncogenic dependence of certain malignancies to specific
signaling pathways or targets, such that inhibition of these
pathways then results in rapid tumor cell death, radiologic
response, and clinical improvement in symptomatic patients.
Crizotinib is associated with relatively mild side effects2 and,
in conjunction with its rapid and dramatic benefits when
administered to patients whose tumors harbor ALK gene
rearrangements, offers the potential to transform some patients’
lives. We cannot emphasize enough the importance of having
sufficient tumor at the time of biopsy when lung cancer is
suspected, so that molecular profiling of the tumor can be
performed, thus allowing the realization of personalized medi-
cine. Although access to crizotinib is available through this
ongoing trial (A8081001, NCT00585195), wider access to cr-
izotinib for ALK-positive patients with NSCLC is available
through participation in the PROFILE trials (A8081005
[NCT00932451] and A8081007 [NCT00932893]).
Finally, screening for ALK gene rearrangement in
NSCLC can be technically challenging. In this case, the
patient’s ALK FISH did not show the common and classic
split 5 (green) and 3 (red) pattern within the same cell but
possessed single isolated red (3 ALK) signals. Indeed, single
red (3 ALK) signal is not rare but is the second most common
FISH pattern in ALK-positive tumors observed by sites par-
ticipating in the phase I crizotinib trial.7
ACKNOWLEDGMENTS
A8081001 is funded and sponsored by Pfizer.
REFERENCES
1. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and
outcome of patients with non-small-cell lung cancer who harbor EML4-
ALK. J Clin Oncol 2009;27:4247–4253.
2. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase
inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–
1703.
3. Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of
EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46:1773–
1780.
4. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements:
a new therapeutic target in a molecularly defined subset of nonsmall cell
lung cancer. J Thorac Oncol 2009;4:1450–1454.
5. Solomon B, Bang Y, Camidge DR, et al. Timing of response to crizotinib
(PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients
with advanced non-small cell lung cancer (NSCLC). 22nd EORTC-NCI-
AACR symposium on molecular targets and cancer therapeutics, Berlin,
Germany. Abstract 369.
6. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: a new
paradigm for imaging. Oncologist 2008;13(Suppl 2):8–13.
7. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung
cancer patients harboring anaplastic lymphoma kinase (ALK) gene rear-
rangements potentially suitable for ALK inhibitor treatment. Clin Cancer
Res. In press.
Ou et al. Journal of Thoracic Oncology • Volume 5, Number 12, December 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer2046
